We report the cytogenetic results obtained in 81 multiple myeloma (MM) patients with abnormal karyotypes. Most karyotypes were complex with numerical and structural abnormalities but the analysis of chromosomal abnormalities allowed identification of two cytogenetic patterns depending on the chromosome number: a first hyperdiploid pattern (54%) with recurrent trisomies 3, 5, 7, 9, 11, 15 and 19 and a second pattern (46%) showing either pseudodiploid, hypodiploid or near-tetraploid karyotypes. Structural abnormalities were present in all but five hyperdiploid karyotypes, and frequently involved lymphoid breakpoints: immunoglobulin gene regions (36 cases) or chromosome 11q13 region (21 cases). Numerous other structural aberrations were detected; the most frequent involved chromosome 1 and chromosome 13. Structural abnormalities were significantly more frequent in the second hypodiploid group. When analyzing the results obtained in the 60 patients studied at the time of diagnosis, a prognostic correlation was found between the cytogenetic pattern and overall survival: hyperdiploid patients had a longer survival than patients belonging to the pseudo/hypo/near-tetraploid group (median survival 36.8 vs 18.2 months, P Ͻ 0.04). These results suggest that MM could correspond to two closely related diseases.
Introduction
During the past few years, several heterogeneous hematological disorders characterized by closely related cell morphology or histology have resolved into distinct well delineated entities, as the result of a better knowledge of their genetic, immunologic or ultrastructural characteristics. Cytogenetic studies largely participate in this task, and furthermore in the identification of genes involved in the genesis of these diseases, allowing a better understanding of the physiopathological processes implicated in tumor development. Good examples of such progress can be found in the fields of acute lymphoid leukemia or non-Hodgkin's lymphoma. In addition, the karyotypic patterns have been shown to correlate with the prognosis of the diseases, and cytogenetic studies or their molecular counterpart are now taken into account for the stratification of treatments. 1 Multiple myeloma (MM) is a B cell neoplasia characterized by the expansion of a malignant plasma cell population within bone marrow, often associated with a low mitotic index leading to difficulties in the cytogenetic detection of the malignant clone. [2] [3] [4] [5] [6] On a morphological and phenotypic basis, MM is considered as a unique but heterogeneous disease. [7] [8] [9] We report the cytogenetic results obtained in a series of 81 MM patients with abnormal karyotypes showing the presence of two different cytogenetic patterns and leading to the evidence that among MM patients with abnormal karyotypes, at least two groups with a different prognosis can be identified.
Materials and methods

Patients
Eighty-one MM patients with clonal chromosomal abnormalities were studied in two different institutions. There were 43 female and 38 male patients. The median age at diagnosis was 64 years (range 35-88). Seventy-three had stage III myeloma whereas only eight had stage I or II, according to Durie and Salmon. 10 Sixty patients were studied at the time of primary diagnosis and were eligible for survival analysis, whereas 21 were karyotyped during follow-up. The monoclonal component was IgG in 55 patients, IgA in 17, IgD in two and seven expressed only light chains. The average percentage of bone marrow plasma cells was 36%. The main clinical, hematological and biochemical characteristics of the patients are listed in Table I . Six patients (cases 15, 20, 51, 61, 62 and 69) had a previous history of monoclonal gammopathy of undetermined significance (MGUS). Patients with therapy-related leukemia were excluded from the study. Clinical and cytogenetic characteristics of some patients have previously been reported. 5 
Treatment regimens
Fifty-eight patients received conventional treatments: either Alexanian (melphalan, prednisolone) or various multidrug regimens: mostly VAD (vincristine, adriamycin, dexamethasone) prolonged by use of ␣-2b-interferon in a number of cases, or VMBCP (vincristine, melphalan, BCNU, cyclophosphamide, prednisolone). Eighteen patients benefitted from high-dose myeloablative chemotherapy with transplant support in 16 cases. Four patients did not receive any therapy.
Cytogenetic analysis
Cytogenetic studies were performed on bone marrow cells cultured in RPMI 1640 medium supplemented with 20% fetal calf serum. In most cases, cells were grown for 3 days without adjunction of cytokines. 5 RHG banding was performed according to Sehested, and chromosomal abnormalities were described according to ICSN. 11 Chromosomal abnormalities were considered as clonal when the same structural rearrangement or chromosome gain was present in at least two mitoses. However, five patients in whom only one typical 
Statistical methods
Overall survival was chosen as the major end point in this study (whatever the cause of death, disease or other causes). Curves were plotted using the method of Kaplan and Meier, 12 and were compared using the log-rank test. 13 Univariate prognostic factor analysis was performed considering the following variables: age, stage, and ␤-2 microglobulin levels, lytic bone marrow lesions, bone marrow plasmocytosis, hemoglobin and creatinine levels, calcemia, monoclonal component isotype, idiotype of light chains, percentage of abnormal metaphases, modal number of chromosomes, and all chromosomal abnormalities occurring in 10% of patients or more. Analysis was performed using the JPSI statistical software (developed by P Kwiatkowski, Centre Jean Perrin, Clermont Ferrand, France.)
Results
Chromosome findings
Abnormal mitosis:
An average of 33.5 metaphases was studied per patient (range 11-119), 9.6 of which (28.5%) were abnormal mitoses. All but four karyotypes showed a mixture of normal and abnormal cells. There was no correlation between the number of abnormal mitosis and the percentage of plasma cells in bone marrow. Complete karyotypes are listed in Table 2 .
Chromosome number
The chromosome number of abnormal clones varied from 38 to 92, but distribution was not continuous, allowing characterization of three different populations of patients ( Figure 1 ).
In the main population (44 patients, 54%), karyotypes were hyperdiploid with an average of 53 chromosomes (range 47-70). The increase of chromosome number appears to be nonrandom since in every case chromosome gain was made of recurrent trisomies involving namely chromosomes 3, 5, 7, 9, 11, 15 and 19 (Table 3 ). An average of five of these trisomies was found per karyotype. In a second population (30 patients, 37%), karyotypes were pseudodiploid or hypodiploid with an average of 44.6 chromosomes (range 38-46); near-tetraploid duplicated metaphases were found in three of these patients.
In a third population (seven patients, 8.6%) karyotypes were mostly near-tetraploid with an average of 87 chromosomes (range 80-93), but a single hypodiploid metaphase bearing the same abnormalities was found in three cases. Regarding both numerical and structural abnormalities, the chromosomal pattern of the pseudo/hypodiploid and near-tetraploid populations was identical, and we considered that they belonged to the same second group referred to as the hypodiploid group. On the other hand, one of the trisomies present in the first hyperdiploid group was found in only five patients of the second group (Table 3) . Loss of chromosome 13 or partial deletion involving the 13q14 region was found in 38 patients, and was mostly associated with the second hypodiploid group (14/44 and 24/37, respectively) ( Table 4) .
Structural abnormalities
Structural abnormalities were always present in the second group, whereas in the first hyperdiploid group, numerical abnormalities were found isolated in five patients. All but three karyotypes with structural abnormalities were complex with an average of 4.3 breaks in the first group, and 6.7 in the second group. Breaks at immunoglobulin gene locations occurred in 36 patients and their distribution within the two groups defined above was significantly different. They concerned mainly the heavy chain region at 14q32 and the 22q11 region. The 2p12 region was implicated in only one patient. Most rearrangements were translocations, involving either non-identified or well characterized material. Recurrent translocations were seven 'Burkitt-like' translocations -four t(8;22)(q24;q11), one masked t(2;8)(p12;q24) confirmed by FISH and two t(8;14)(q24;q32) -and 11 t(11;14)(q13;q32). Six of the Burkitt translocations were found in the hyperdiploid Continued 80ෂ86Ͻ4nϾ,XXYY,−1,−1,+3,−4,add(6)(q11)×2,−7,del(7)(p11)×2,der(7)t(1;7)(q11?;p21?).ish der(7)t(1;7)(q11;p21?)(wcp1+),+9,del(11)(p13)×2,+del(11)(q13),−12,−13,−13,−14,−14,der (14) group and one in the hypodiploid group, whereas 10 out of 11 t(11;14) were found in the hypodiploid patients (Tables 3  and 4) . Several regions were involved in more than 10% of patients, namely: chromosome 1 short arm (mostly interstitial deletion p11-p21 or p22-p32), chromosome 1 long arm leading to total or partial duplications, chromosome 4 long arm, chromosome 6 long arm, the 8q24 region, and the 11q13 region implicated either in simple deletions or in translocations, mainly the t(11;14) as mentioned above. In some cases, structural abnormalities appeared as clonal evolution and thus represent secondary events: del1p, a 'Burkitt-like' translocation, 8q24 or 22q11 involvement (cases 3, 18, 19, 41 and 65).
Survival
In the 60 patients studied at the time of MM diagnosis, several well known prognostic factors [14] [15] [16] were found to correlate with survival in univariate analysis: adverse prognostic was observed in patients with hemoglobin р 8.5 dl/100 ml (13 of 59 patients, median survival 5.5 vs 31 months, P Ͻ 0.001), bone marrow plasmocytosis Ͼ 30% (31 of 60 patients, 16.6 vs 34.4 months, P Ͻ 0.02), creatinine Ͼ 200 mol/l (11 of 60 patients, 12.9 vs 29.8, P Ͻ 0.04) and ␤-2 microglobulin у 5 mg/l (17 of 48 patients, 15.1 vs 34.4, P Ͻ 0.02). The stage could not be tested as 54 of 60 patients were stage III. All other clinical parameters tested, namely age, calcemia, lytic bone lesions, monoclonal component isotype, idiotype of light chain, did not influence survival in this series. Cytogenetic results correlate with overall survival: the chromosome number was found to influence the outcome (Figure 2 ). Patients with a hypo/pseudodiploid or near-tetraploid karyotype had a worse prognosis than patients with a hyperdiploid karyotype (18.2 vs 36.8 months, P Ͻ 0.04). Several individual structural abnormalities also had a negative impact on survival: breaks in Ig gene regions (31 of 60 patients, median survival 14.8 vs 37.6 months, P Ͻ 0.02), involvement of 11q13 (18 of 60 patients, 12 vs 34.6, P Ͻ 0.01) and involvement of the long arm of chromosome 4 (six of 60 patients, 9 vs 29.7, P Ͻ 0.01). Conversely, other abnormalities did not influence survival, in particular total or partial deletion of chromosome 13 (27 of 60 patients, 22.6 vs 26.6), involvement of chromosome 1, breaks at 8q24 and the percentage of abnormal mitoses. The median follow-up of 24 living patients was 24.6 months (range 3-75).
Discussion
Conventional cytogenetics allow the detection of clonal changes in about 30 to 50% MM patients. 2, 4, [17] [18] [19] A number of techniques have been investigated in order to increase the detection rate of abnormal clones; [2] [3] [4] [5] [6] nevertheless, a large number of normal karyotypes are still reported, mainly in smoldering diseases. 20 When only normal metaphases are identified, it has been shown that they originate from the normal hematopoietic component 2 and additional techniques, such as flow cytometry or interphase fluorescence in situ hybridization are able to detect genomic defects in almost all patients whatever the stage of disease. [20] [21] [22] [23] [24] [25] [26] We have analyzed the results obtained in a series of 81 MM patients with abnormal karyotypes. In this series, the distribution of the chromosome number appears essentially bimodal, allowing definition of two groups: in the first one, karyotypes are hyperdiploid with non-random gains of chromosomes 3, 5, 7, 9, 11, 15 and 19; in the second, karyotypes are pseudo/hypo or neartetraploid. Structural abnormalities were detected in 76 patients and the five patients in whom such anomalies were not identified belong to the first hyperdiploid group.
Chromosome breaks correspond either to regions usually implicated in lymphoid malignancies such as Ig gene regions, 11q13, 8q24, or to regions known to be involved in tumor progression: long arm chromsome 1 and 13 27, 28 or to regions reported as specifically rearranged in MM: short arm of chromosome 1 and the long arm of chromosome 6. 29 Besides, a number of other recurrent, non-random breakpoints were found in less than 10% of patients and are not discussed here. The distribution of structural abnormalities was not homogeneous between the two groups defined by the chromosome number. The average number of breaks was higher in the second group than in the first one. As shown in Tables 3 and  4 , t (11;14) was associated with the hypodiploid pattern whereas 'Burkitt's-type' translocations were mainly found in the hyperdiploid group. In the same way, rearrangements involving chromosome 1 long arm and partial or total deletion of chromosome 13 were twice as frequent in the second group. Taken together, these results allow definition of two chromosomal patterns in MM: (1)-a hyperdiploid pattern with non-random gains of chromosomes 3, 5, 7, 9, 11, 15 and 19 with or without secondary structural aberrations, including 'Burkitt's-type' translocations and (2) a pseudo/ hypodipoid/near-tetraploid pattern associated with complex structural aberrations, including the t(11;14) translocation. Only three patients could not be included in the groups defined above: two had non-complex pseudodiploid karyotypes, and the third one had a hyperdiploid karyotype but none of the trisomies present in all the other hyperdiploid patients. These cytogenetic results are in agreement with previously reported large series regarding chromosome gains, and most structural abnormalities involving chromosomes 1, 11, 13 and 14. [2] [3] [4] [17] [18] [19] . However, among breaks found in about 10% of patients, differences can be noted: implication of chromosome 19 reported as specific of MM 29 was found in only 9% of our patients.
The present series includes 60 karyotypes studied in untreated patients at diagnosis and 21 studied during followup in previously treated patients. We did not find any cytogenetic difference between the results obtained at diagnosis and those obtained during evolution. Furthermore, follow-up karyotypes performed after conventional chemotherapy were identical to those found at diagnosis in eight patients, whereas normal metaphases were found in only four patients achieving complete remission after high-dose chemotherapy. These findings are not in agreement with those reported by Clark et al 30 who found only hyperdiploid karyotypes in untreated patients and hypodiploid karyotypes in previously treated patients.
Previous reports on the prognostic value of cytogenetic in MM are mainly based on series taking into account both nor-
Figure 2
Overall survival of 60 patients analyzed at time of primary diagnosis according to the number of chromosomes. 1, hyperdiploid patients; 2, hypodiploid patients. mal and abnormal karyotypes. In such series, the number of normal karyotypes makes it difficult to demonstrate the prognostic value of any chromosomal pattern or individual defect. Poor response to therapy of hypodiploid patients vs other patients was first reported by Gould et al 18 and recently by Calasanz et al. 31 Likewise, flow cytometry studies demonstrated a different outcome according to the DNA content: for Smith et al, 23 hypodiploid and biclonal myeloma did not respnd to chemotherapy. The biclonal pattern of these patients could correspond to the hypo and/or near-tetraploid karyotypes. Hyperdiploidy was found to correlate with a better prognosis. 32 In these series of 60 patients with abnormal karyotypes studied before treatment, the chromosome number was found to correlate with overall survival (Figure 2 ): the hyperdiploid patients had a longer survival than hypodiploid patients. This difference appeared independent from treatment since the distribution of various regimens was comparable in the two groups (13 vs 10 standard chemotherapy and 18 vs 16 highdose chemotherapy). In the whole series, structural abnormalities involving Ig gene location were found to influence survival. However, when analyzed separately in the two groups defined by the chromosome number we found that Ig gene involvement confers a bad prognosis for hyperdiploid patients (13 of 34 patients, median survival 11.5 vs 43.8, P Ͻ 0.02), but did not influence the poor survival in the hypodiploid group (18 of 26, 20 vs 14 months, NS). Involvement of 11q13 appears as an adverse factor, with a median survival of 12 months whatever the chromosome number. However, 14 out of 18 patients with such involvement belonged to the hypodiploid group. The adverse significance of 11q implication was previously reported by Tricot et al. 33, 34 Conversely, in agreement with the results reported by Calasanz et al, 31 the present study did not confirm the poor outcome associated with partial or total deletion of chromosome 13. [33] [34] [35] The conflicting results could be explained by the fact that our correlations were established on a series including only abnormal karyo types, and that our patients received different treatment regimens while all the patients reported by Tricot et al 33 entered an identical intensive treatment program.
Within the complex and heterogeneous MM karyotypes this study identifies two different homogeneous patterns, allowing a more comprehensive interpretation of cytogenetic changes primarily based on the chromosome number and correlated with the clinical outcome. Those two patterns suggest that MM, usually referred to as a unique but heterogeneous disease, could be reconsidered either as two closely related diseases or as a single primary disease with two distinct evolutionary pathways. This interpretation could explain the results obtained by flow cytometry methods, as patients belong either to a poor prognosis hypo/pseudo/near-tetraploid group or to a better hyperdiploid group. In this latter group, however, an acquired Ig gene rearrangement represents an adverse prognostic factor. Those results have to be confirmed on larger series, with longer follow-up. Their prognostic value has to be re-evaluated in patients receiving identical treatments, as intensive chemotherapy seems to improve survival even in patients with bad prognostic factors. 36 
